News

TOKYO, June 11, 2018  - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it launched 40 mg XTANDI® (generic name enzalutamide) Tablets and 80 mg XTANDI® Tablets in Japan for the treatment of castration-resistant prostate cancer, which add additional dosage forms to the previously available 40 mg XTANDI® Capsules. XTANDI® is an oral androgen receptor...

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-  TOKYO and BOTHELL, Wash. – June 3, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the presentation of updated phase 1 data of enfortumab vedotin, an...

TOKYO – May 31, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the launch of the third annual Astellas Oncology C3 Prize (Changing Cancer Care), a global challenge aimed at inspiring non-treatment ideas that may improve cancer care for patients and their loved ones. This year’s challenge will focus on solutions for cancer care in low-...

TOKYO and San Francisco, May 31, 2018  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, “FibroGen”) today announced that the fourth Japan Phase 3 study for roxadustat met its primary endpoint. This study evaluated the efficacy and safety of roxadustat compared to darbepoetin alfa (genetical recombination...